Comparison of non-inferiority of two treatment algorithms (discretion of the investigator vs. pro re nata) of 0.5 mg ranibizumab in patients with visual impairment due to diabetic macula edema

Update Il y a 4 ans
Reference: EUCTR2014-002854-37

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is to demonstrate that the mean average change of BCVA in patients with DME treated with ranibizumab injections at the discretion of the investigator (DI) and in accordance with disease activity criteria is non-inferior to current standard of care (PRN).


Inclusion criteria

  • visual impairment due to diabetic macular edema

Links